- Myasthenia gravis and immune thrombocytopenia named as initial indications for Phase 2 studies of ARGX-113
- T-cell lymphoma and acute myeloid leukemia named as indications for Phase 2 combination studies for ARGX-110
Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided highlights from its lead pipeline programs, ARGX-113 and ARGX-110, during its R&D in New York City.
An archived webcast of the event is available for download on the Company’s website at www.argenx.com.
We are very pleased to announce today our strategic plan for driving forward our antibody pipeline through 2017; it includes several important value creating events including two Phase 2 studies in important autoimmune indications for ARGX-113 and two combination studies in serious hematological malignancies for ARGX-110, said Tim Van Hauwermeiren, CEO of argenx. We’re particularly proud of the speed of our development plan and look forward to continuing to advance our entire pipeline rapidly towards becoming an integrated drug development company.
Members of argenx management as well as guest speakers Dr. James Howard from the University of North Carolina, Dr. Adrian Newland from The Royal London Hospital, and Dr. Owen O’Connor from Columbia University presented the following program highlights:
ARGX-113
ARGX-113 is a potential breakthrough therapy for the treatment of IgG-mediated autoimmune diseases. It is the Fc-portion of an antibody enhanced by argenx proprietary ABDEG™ technology to block the recycling receptor FcRn leading to fast depletion of IgGs, including autoimmune disease-causing IgG’s. In June 2016, argenx announced favorable safety and tolerability, and efficacy data from its Phase 1 multiple ascending dose study in healthy volunteers. Early pharmacodynamic results showed selective and potent IgG reduction of up to 85%.
Today, argenx announces further results from the Phase 1 study of ARGX-113, across multiple doses and dosing regimens, and its plan to advance ARGX-113 into Phase 2 studies in myasthenia gravis (MG) and immune thrombocytopenic purpura (ITP). argenx plans to open the MG study before the end of the year and the ITP study shortly thereafter.
ARGX-110
ARGX-110 is a SIMPLE Antibody™ that potently blocks CD70-induced tumor cell proliferation and tumor escape from immune surveillance. It is currently being studied in an ongoing Phase 1b expansion cohort in patients with relapsed/refractory T-cell lymphoma (TCL).
Today, argenx announced new patient anecdotes from its Phase 1b safety expansion cohort showing a favorable safety profile and biological activity in cutaneous T-cell lymphoma (CTCL) patients, evidenced by biomarker data and clinical disease score. The results established the Phase 2 dose and also refined the biomarkers to be used to assess the ongoing effects of ARGX-110 in TCL patients. The Company presented its plan to study ARGX-110 in two combination studies in TCL and AML, both with the respective standard of care. argenx aims to initiate at least one combination study before the end of the year.
About argenx
argenx (ARGX) combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders and academic experts contribute to the success of our journey. www.argenx.com
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should, and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’ actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
